These diseases are related to deregulation of insulin (IN) and insulin-like growth factors (IGFs) signaling, which are also expected to influence RCC tumorigenesis and progression (Solarek et al. 2015; Labochka et al. 2016; Tracz et al. 2016). This evidence concerns the gene INS and renal cell adenocarcinoma.